These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 1818147)
1. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147 [TBL] [Abstract][Full Text] [Related]
2. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Schmatz DM; Powles MA; McFadden D; Nollstadt K; Bouffard FA; Dropinski JF; Liberator P; Andersen J Antimicrob Agents Chemother; 1995 Jun; 39(6):1320-3. PubMed ID: 7574523 [TBL] [Abstract][Full Text] [Related]
3. Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy. Matsumoto Y; Yamada M; Amagai T J Protozool; 1991; 38(6):6S-7S. PubMed ID: 1818205 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Schmatz DM; Romancheck MA; Pittarelli LA; Schwartz RE; Fromtling RA; Nollstadt KH; Vanmiddlesworth FL; Wilson KE; Turner MJ Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5950-4. PubMed ID: 2198575 [TBL] [Abstract][Full Text] [Related]
5. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Schmatz DM; Powles MA; McFadden DC; Pittarelli L; Balkovec J; Hammond M; Zambias R; Liberator P; Anderson J Antimicrob Agents Chemother; 1992 Sep; 36(9):1964-70. PubMed ID: 1416888 [TBL] [Abstract][Full Text] [Related]
6. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Ito M; Nozu R; Kuramochi T; Eguchi N; Suzuki S; Hioki K; Itoh T; Ikeda F Antimicrob Agents Chemother; 2000 Sep; 44(9):2259-62. PubMed ID: 10952565 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. Sun P; Tong Z Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652 [TBL] [Abstract][Full Text] [Related]
8. Evidence for DNA synthesis in Pneumocystis carinii trophozoites treated with the beta-1,3-glucan synthesis inhibitor pneumocandin L-693,989. Wyder MA; Johnston LQ; Kaneshiro ES J Eukaryot Microbiol; 2010; 57(5):447-8. PubMed ID: 20738464 [TBL] [Abstract][Full Text] [Related]
9. An experimental trial of artemether in treatment of Pneumocystis carinii in immunosuppressed rats. Chen YT; Ma L; Mei Q; Tang Y; Liao XG Chin Med J (Engl); 1994 Sep; 107(9):673-7. PubMed ID: 7805459 [TBL] [Abstract][Full Text] [Related]
10. Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats. Powles MA; McFadden DC; Liberator PA; Anderson JW; Vadas EB; Meisner D; Schmatz DM Antimicrob Agents Chemother; 1994 Jun; 38(6):1397-401. PubMed ID: 8092844 [TBL] [Abstract][Full Text] [Related]
11. Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560. Nollstadt KH; Powles MA; Fujioka H; Aikawa M; Schmatz DM Antimicrob Agents Chemother; 1994 Oct; 38(10):2258-65. PubMed ID: 7840554 [TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703 [TBL] [Abstract][Full Text] [Related]
13. Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Tamburrini E; Mencarini P; Visconti E; De Luca A; Zolfo M; Siracusano A; Ortona E; Murri R; Antinori A J Med Microbiol; 1996 Aug; 45(2):146-8. PubMed ID: 8683551 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Powles MA; Liberator P; Anderson J; Karkhanis Y; Dropinski JF; Bouffard FA; Balkovec JM; Fujioka H; Aikawa M; McFadden D; Schmatz D Antimicrob Agents Chemother; 1998 Aug; 42(8):1985-9. PubMed ID: 9687394 [TBL] [Abstract][Full Text] [Related]
15. [New aspects of epidemiology and treatment of Pneumocystis carinii infection]. Powierska-Czarny J; Gospodarek E; Czerwionka-Szaflarska M Pol Merkur Lekarski; 2004 Nov; 17(101):534-7. PubMed ID: 15754652 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of beta-D glucan in diagnosing Pneumocystis carinii pneumonia and monitoring its treatment in a living-donor liver-transplant recipient. Kawagishi N; Miyagi S; Satoh K; Akamatsu Y; Sekiguchi S; Satomi S J Hepatobiliary Pancreat Surg; 2007; 14(3):308-11. PubMed ID: 17520208 [TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment and prophylaxis of Pneumocystis carinii pneumonia. Warren E; George S; You J; Kazanjian P Pharmacotherapy; 1997; 17(5):900-16. PubMed ID: 9324180 [TBL] [Abstract][Full Text] [Related]
18. Trophozoite-to-cyst ratio increases during recovery from Pneumocystis carinii pneumonia in rats. Sukura A APMIS; 1995 Apr; 103(4):300-6. PubMed ID: 7612261 [TBL] [Abstract][Full Text] [Related]
19. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia. Warnock AC; Rimland D Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975 [TBL] [Abstract][Full Text] [Related]
20. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. Schmatz DM; Abruzzo G; Powles MA; McFadden DC; Balkovec JM; Black RM; Nollstadt K; Bartizal K J Antibiot (Tokyo); 1992 Dec; 45(12):1886-91. PubMed ID: 1490879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]